Literature DB >> 458563

Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits.

V H Lee, J R Robinson.   

Abstract

The low ocular bioavailability of topically applied pilocarpine is attributed to extensive precorneal drug loss in conjection with the resistance to corneal penetration. Several elements of precorneal loss were reported earlier, but a complete mechanistic understanding has not been available. The present study was designed to gain a better understanding of the mechanisms governing pilocarpine disposition in the precorneal areas as well as the relative influence of these parameters on ocular drug bioavailability. Radioactive pilocarpine and glycerin solutions were instilled into the precorneal area of the albino rabbit eye under various experimental conditions, and the drug concentration in the lacrimal lake was monitored as a function of time. The results demonstrated that nonconjunctival loss of pilocarpine, vasodilation due to the drug, and lacrimation due to vehicle formulation are additional aspects of precorneal drug disposition. The individual influence of all precorneal loss parameters on drug bioavailability was then assessed using a mathematical model formulated from experimental findings on both precorneal and intraocular drug disposition. Drainage and vasodilation, as well as nonconjunctival pilocarpine loss, exerted major influences on drug loss at the absorption site.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458563     DOI: 10.1002/jps.2600680606

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  28 in total

1.  Bioavailability of fluorescein from a new drug delivery system in human eyes.

Authors:  A Steinfeld; A Lux; S Maier; R Süverkrüp; M Diestelhorst
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

2.  Biopharmaceutical evaluation of ibufenac, ibuprofen, and their hydroxyethoxy analogs in the rabbit eye.

Authors:  C S Rao; R D Schoenwald; C F Barfknecht; S L Laban
Journal:  J Pharmacokinet Biopharm       Date:  1992-08

3.  General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.

Authors:  Feng Deng; Veli-Pekka Ranta; Heidi Kidron; Arto Urtti
Journal:  Pharm Res       Date:  2016-07-18       Impact factor: 4.200

4.  Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions.

Authors:  N M Davies; S J Farr; J Hadgraft; I W Kellaway
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

Review 5.  Ocular drug delivery. Pharmacokinetic considerations.

Authors:  R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

6.  Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.

Authors:  Sudharshan Hariharan; Sriram Gunda; Gyan P Mishra; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

7.  Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line.

Authors:  P Saarinen-Savolainen; T Järvinen; K Araki-Sasaki; H Watanabe; A Urtti
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

Review 8.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

9.  Ocular pharmacokinetic models of clonidine-3H hydrochloride.

Authors:  C H Chiang; R D Schoenwald
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

10.  Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparticles).

Authors:  R Diepold; J Kreuter; J Himber; R Gurny; V H Lee; J R Robinson; M F Saettone; O E Schnaudigel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.